From Knowledge to Action: Final Takeaways for Oncology Pharmacists Implementing Bispecific Therapy

In the final episode, 'From Knowledge to Action: Final Takeaways for Oncology Pharmacists Implementing Bispecific Therapy,' the panelists explored the following critical question:

Looking across everything we've discussed today, such as earlier use, safety management, and transitions of care in bispecifics, what is the one thing you want every oncology pharmacist watching this program to walk away and do differently, starting tomorrow?

Led by the moderator, the panelists closed with practical, immediately actionable guidance for oncology pharmacists at every stage of bispecific antibody program development. They encouraged those who feel intimidated by starting a new program to reach out to colleagues who have already built and refined their processes, emphasizing that there is no secret ingredient to a successful bispecific program and that established SOPs, protocols, and hard-won institutional knowledge are things experienced centers are genuinely willing to share, particularly as these therapies expand into more disease states and more oncology infusion rooms become the de facto administration site regardless of subspecialty focus. The panelists offered an empowering message centered on clinical confidence, urging pharmacists to know their data and let it be their ally, reminding the audience that the vast majority of CRS events are Grade 1 fevers that do not require emergency intervention, that prophylactic strategies including low-dose tocilizumab and pocket dexamethasone have reduced that low-grade risk, and that understanding and communicating this data to nursing teams, emergency departments, and community partners is the single most powerful thing a pharmacist can do to expand safe access to these transformative therapies. Zahra Mahmoudjafari closed by reinforcing that pharmacists are uniquely positioned to bridge the gap between clinical data and operational implementation and extended an open invitation to the viewing audience to reach out to any of the panelists for guidance, support, or collaboration as the bispecific antibody landscape continues to evolve.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Practice Pearls series on multiple myeloma. Please subscribe to our newsletter for information on upcoming video series.